AR060992A1 - Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia - Google Patents
Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemiaInfo
- Publication number
- AR060992A1 AR060992A1 ARP070102010A ARP070102010A AR060992A1 AR 060992 A1 AR060992 A1 AR 060992A1 AR P070102010 A ARP070102010 A AR P070102010A AR P070102010 A ARP070102010 A AR P070102010A AR 060992 A1 AR060992 A1 AR 060992A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- difenylpirimidinylamine
- glucemia
- procedures
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000004419 alkynylene group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 4,5-diphenylpyrimidinylamino Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001735 carboxylic acids Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021874A DE102006021874B4 (de) | 2006-05-11 | 2006-05-11 | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060992A1 true AR060992A1 (es) | 2008-07-30 |
Family
ID=38326940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102010A AR060992A1 (es) | 2006-05-11 | 2007-05-09 | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7713988B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2024340B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5277159B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090006845A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101421251B (cg-RX-API-DMAC7.html) |
| AR (1) | AR060992A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007250211B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0711393A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2651657A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE102006021874B4 (cg-RX-API-DMAC7.html) |
| IL (1) | IL195177A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008014101A (cg-RX-API-DMAC7.html) |
| MY (1) | MY148096A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20085066L (cg-RX-API-DMAC7.html) |
| TW (1) | TW200815366A (cg-RX-API-DMAC7.html) |
| UY (1) | UY30339A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007131620A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
| CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| ES2446419T3 (es) | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| JP2011515341A (ja) | 2008-03-06 | 2011-05-19 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 |
| EP2358656B1 (en) | 2008-10-15 | 2014-01-01 | Amgen, Inc | Spirocyclic gpr40 modulators |
| BRPI0922233A2 (pt) * | 2008-12-08 | 2018-05-29 | Euroscreen Sa | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| WO2011140190A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Tetrazolones as inhibitors of fatty acid synthase |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| BR112013004882A2 (pt) | 2010-08-31 | 2016-05-03 | Snu R&Db Foundation | utilização de reprogramação fetal de agonista ppar delta |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| CN118084940A (zh) | 2018-02-13 | 2024-05-28 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| AU2019255750B2 (en) | 2018-04-19 | 2021-10-21 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004029204A2 (en) * | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| NZ550114A (en) * | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
2006
- 2006-05-11 DE DE102006021874A patent/DE102006021874B4/de not_active Expired - Fee Related
-
2007
- 2007-04-30 CN CN2007800133035A patent/CN101421251B/zh not_active Expired - Fee Related
- 2007-04-30 KR KR1020087027548A patent/KR20090006845A/ko not_active Abandoned
- 2007-04-30 CA CA002651657A patent/CA2651657A1/en not_active Abandoned
- 2007-04-30 AU AU2007250211A patent/AU2007250211B2/en not_active Ceased
- 2007-04-30 MX MX2008014101A patent/MX2008014101A/es not_active Application Discontinuation
- 2007-04-30 EP EP07724731A patent/EP2024340B1/de not_active Not-in-force
- 2007-04-30 BR BRPI0711393-5A patent/BRPI0711393A2/pt not_active IP Right Cessation
- 2007-04-30 WO PCT/EP2007/003804 patent/WO2007131620A1/de not_active Ceased
- 2007-04-30 JP JP2009508191A patent/JP5277159B2/ja not_active Expired - Fee Related
- 2007-05-09 AR ARP070102010A patent/AR060992A1/es not_active Application Discontinuation
- 2007-05-09 TW TW096116359A patent/TW200815366A/zh unknown
- 2007-05-10 UY UY30339A patent/UY30339A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 MY MYPI20084448A patent/MY148096A/en unknown
- 2008-11-09 IL IL195177A patent/IL195177A0/en unknown
- 2008-11-10 US US12/267,918 patent/US7713988B2/en not_active Expired - Fee Related
- 2008-12-04 NO NO20085066A patent/NO20085066L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20085066L (no) | 2009-02-06 |
| US7713988B2 (en) | 2010-05-11 |
| MY148096A (en) | 2013-02-28 |
| EP2024340B1 (de) | 2012-07-18 |
| CA2651657A1 (en) | 2007-11-22 |
| UY30339A1 (es) | 2008-01-02 |
| JP2009536627A (ja) | 2009-10-15 |
| KR20090006845A (ko) | 2009-01-15 |
| BRPI0711393A2 (pt) | 2011-11-01 |
| AU2007250211A1 (en) | 2007-11-22 |
| MX2008014101A (es) | 2008-11-14 |
| AU2007250211B2 (en) | 2011-11-10 |
| WO2007131620A1 (de) | 2007-11-22 |
| CN101421251A (zh) | 2009-04-29 |
| DE102006021874B4 (de) | 2008-03-27 |
| IL195177A0 (en) | 2009-08-03 |
| US20090149487A1 (en) | 2009-06-11 |
| DE102006021874A1 (de) | 2007-11-22 |
| JP5277159B2 (ja) | 2013-08-28 |
| TW200815366A (en) | 2008-04-01 |
| HK1130800A1 (en) | 2010-01-08 |
| CN101421251B (zh) | 2011-10-19 |
| EP2024340A1 (de) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060992A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para la preparacion de productos farmaceuticos, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para la reduccion de la glucemia | |
| AR060993A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidiniloxi o mercapto, procedimiento para su preparacion y su uso como productos farmaceuticos | |
| AR060991A1 (es) | Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes | |
| AR060990A1 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes | |
| AR035498A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| AR003440A1 (es) | Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados. | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
| AR029463A1 (es) | Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR063942A1 (es) | Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c | |
| CL2010000434A1 (es) | Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica. | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| AR051340A1 (es) | Compuesto de c(4)- metoximetil acil pirrolidina, su uso para preparar un medicamento, formulacion farmaceutica que lo comprende y proceso para prepararlo | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ECSP066330A (es) | Derivados de 1-sulfonilindol, su preparación y su uso como lingados de 5-ht-6 | |
| AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
| AR037560A1 (es) | Formulacion de altas dosis de ibandronato | |
| ECSP066325A (es) | Derivados de 5-indolilsulfonamidas, su preparación y su uso como moduladores de 5-ht-6 | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| AR059045A1 (es) | Composicion farmaceutica y proceso | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |